Associate Professor, Haematology
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD (as Co-Supervisor) - email supervisor to discuss availability.
With unique training experience at the Stanford School of Medicine, including mentoring from Professors Ravindra Majeti, Irving Weissman, Hiro Nakauchi and Craig Jordan (UC Denver), Daniel Thomas is a clinical haematologist and pathologist whose goals in research are to develop new drugs for the treatment of cancer and lead a productive cutting-edge cancer research group in Australia.
The Thomas Lab on level 5 of SAHMRI (Precision Medicine, Cancer Theme) is focused on interplay between cancer, metabolism and epigenetics using myeloid cells as a human in vivo platform to discover new targets for common mutations that cause cancer. Dr Daniel Thomas is a clinical haematologist and pathologist whose goals in research are to develop new drugs for the treatment of cancer. He has had unique training experience at the Stanford School of Medicine with mentors who have discovered human stem cell populations in blood and bone marrow including Professor Ravindra Majeti, Irving Weissman and Hiro Nakauchi. If you are passionate about thinking outside the square to improve the treatment of cancer, please contact Dr Thomas about potential student internships.
The Thomas Lab has a strong track record in finding new druggable targets in cancer and predicting mutations that respond to specific targeted therapies as well as repurposing old drugs for new uses in cancer. Some of the discoveries that Dr Thomas has contributed to are already in the clinic or are under clinical investigation. These include (i) discovery mutation-specific drug targets for acute myeloid leukaemia (EZH2 for AML with WT1 mutation, Blood 2015; Bcl2 for AML with IDH1 mutation, Nature Med 2016; ROS activation for AML with NPM1 mutation, Leukemia 2014; ACC1 for AML with IDH1 mutation, Nature Com, 2017), (ii) prediction of 145,891 synthetic partners for 3,120 recurrent mutations for 12 cancer types (Leukemia 2019, first author and co-inventor Nature Com, 2017, (iii) pre-clinical development of a biological therapy (humanized monoclonal antibody directed against CD123 Cell Stem Cell, 2009, Leukemia 2014) and (iv) comprehensive translational experience in the development of a novel class of small molecular inhibitor for cancer in the Stanford Alliance for Innovative Medicines program.
Dr Thomas has been awarded a number of prizes for his work including the CSL Centenary Fellowship ($1.25M), K99-R00 Pathway to Independence award by the National Cancer Institute, NHMRC PhD award, Albert Bakie Medal, Douglas Hardy Prize, Nimmo Prize and CJ Martin Biomedical Fellowship.
The over-arching goal of Dan’s research is to find novel mutation-specific drug targets for somatic mutations, especially in poor prognosis and difficult to treat cancer types, using leukemia as a test bed. The lab has unique skills in developing humanized in vivo models for AML, isolation and testing of pre-leukemia stem cells and bioinformatic algorithms together with key academic and industry networks.
Date Position Institution name 2019 Titleholder Stanford University School of Medicine 2019 Associate Professor South Australian Health and Medical Research Institute 2017 - 2019 Instructor/Junior Faculty Stanford University School of Medicine 2010 - 2012 Staff Specialist Royal Adelaide Hospital 2000 - 2000 Resident Royal Adelaide Hospital
Awards and Achievements
Date Type Title Institution Name Country Amount 2018 Award Stanford Alliance of Innovative Medicines Award Stanford University United States — 2015 Award Honorary Award for Outstanding Presentation, Stanford Hematology-Oncology Retreat Stanford University School of Medicine United States — 2015 Award Outstanding External Grant Reviewer for 2014 National Health and Medical Research Council of Australia Australia — 2014 Award Best Publication for Previous Year Centre for Cancer Biology Australia — 2014 Award Leukemia Foundation New Investigator Award Leukemia Foundation Australia — 2014 Award Outstanding Young Investigator Award, New Directions in Leukemia Research Conference New Directions in Leukemia Research Australia — 2012 Distinction Dean’s Commendation for Doctoral Thesis Excellence for PhD The University of Adelaide Australia — 2011 Fellowship HOTT Haematology/Oncology Targetted Therapy Fellowship Haematology Society of Australia & New Zealand/COSA/Roche/COGA Australia — 2010 Award Nimmo Prize, Best Full-Time Research Royal Adelaide Hospital Australia — 2010 Award Outstanding Research Presentation Prize, New Directions in Leukaemia Conference New Directions in Leukaemia Research (NDLR) Australia — 2010 Fellowship HSANZ Haematology Targeted Therapy Fellowship The Haematology Society of Australia and New Zealand Australia — 2008 Award National Adult Medicine Research Award Royal Australasian College of Physicians Australia — 2007 Award Albert Baikie Memorial Medal Haematology Society of Australia & New Zealand Australia — 2007 Award John Chalmers Prize for Best Medical Research Presentation Royal Australasian College of Physicians Australia — 2007 Scholarship The NHMRC Postgraduate Scholarship National Health & Medical Research Council Australia — 2004 Award Hugh Gilmore Prize for Best Presentation of Medical Research by a Physician in Training Royal Adelaide Hospital Australia —
Date Institution name Country Title 2012 University of Adelaide Australia PhD 2000 University of Adelaide Australia Bachelor of Medicine and Bachelor of Surgery 1998 University of Adelaide Australia Bachelor of Medical Science (Honours)
Date Title Institution Country 2012 - 2013 Postdoctoral Fellow Stanford University School of Medicine United States
Date Title Institution name Country 2007 Fellow (FRACP) Royal Australasian College of Physicians Australia 2007 Fellow (FRCPA) Royal College of Pathologists of Australasia Australia
Year Citation 2019 Benard, B., Gentles, A., Köhnke, T., Majeti, R., & Thomas, D. (2019). Data mining for mutation-specific targets in acute myeloid leukemia. Leukemia, 33(4), 826-843.
2019 Benard, B., & Thomas, D. (2019). Predicting response to new drugs in AML from simulation modelling: Value of the BEAT AML project as a validation resource. Leukemia Research, 80, 43-44.
2018 Gars, E., Kaur, S., & Thomas, D. (2018). Endothelin receptor emerges as a potential target of Hoxa9-mediated leukemogenesis. Leukemia Research, 75, 69-70.
2018 Tvorogov, D., Thomas, D., Liau, N., Dottore, M., Barry, E., Lathi, M., . . . Lopez, A. (2018). Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances, 4(11), 1-12.
DOI Scopus1 WoS1 Europe PMC1
2017 Powell, J., Lewis, A., Zhu, W., Toubia, J., Pitman, M., Wallington-Beddoe, C., . . . Pitson, S. (2017). Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia.. Blood, 129(6), 771-782.
DOI Scopus24 WoS22 Europe PMC16
2017 Sinha, S., Thomas, D., Chan, S., Gao, Y., Brunen, D., Torabi, D., . . . Dill, D. (2017). Systematic discovery of mutation-specific synthetic lethals by mining pan-cancer human primary tumor data. Nature Communications, 8, 1-13.
DOI Scopus16 Europe PMC8
2017 Thomas, D., & Majeti, R. (2017). Optimizing next-generation AML therapy: Activity of mutant IDH2 inhibitor AG-221 in preclinical models. Cancer Discovery, 7(5), 459-461.
DOI Scopus10 Europe PMC4
2017 Thomas, D., & Majeti, R. (2017). Biology and relevance of human acute myeloid leukemia stem cells. Blood, 129(12), 1577-1585.
DOI Scopus65 Europe PMC36
2016 Thomas, D., & Majeti, R. (2016). Burning Fat Fuels Leukemic Stem Cell Heterogeneity. Cell Stem Cell, 19(1), 1-2.
DOI Scopus5 Europe PMC11
2016 Huang, M., Garcia, J., Thomas, D., Zhu, L., Truong Nguyen, L., Chan, S., . . . Mitchell, B. (2016). Autophagy mediates proteolysis of NPM1 and HEXIM1 and sensitivity to BET inhibition in AML cells. Oncotarget, 7(46), 74917-74930.
DOI Scopus5 Europe PMC5
2016 Reinisch, A., Thomas, D., Corces, M., Zhang, X., Gratzinger, D., Hong, W., . . . Majeti, R. (2016). A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells. Nature Medicine, 22(7), 812-821.
DOI Scopus73 Europe PMC55
2016 Smith, A., Dun, M., Lee, E., Harrison, C., Kahl, R., Flanagan, H., . . . Verrills, N. (2016). Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. Oncotarget, 7(30), 47465-47478.
DOI Scopus20 WoS16 Europe PMC9
2015 Mazumdar, C., Shen, Y., Xavy, S., Zhao, F., Reinisch, A., Li, R., . . . Majeti, R. (2015). Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor Differentiation. Cell Stem Cell, 17(6), 675-688.
DOI Scopus66 Europe PMC52
2015 Raval, A., Behbehani, G., Nguyen, L., Thomas, D., Kusler, B., Garbuzov, A., . . . Mitchell, B. (2015). Reversibility of defective hematopoiesis caused by telomere shortening in telomerase knockout mice. PLoS ONE, 10(7), 1-20.
DOI Scopus9 Europe PMC7
2015 Reinisch, A., Etchart, N., Thomas, D., Hofmann, N., Fruehwirth, M., Sinha, S., . . . Strunk, D. (2015). Epigenetic and in vivo comparison of diverse MSC sources reveals an endochondral signature for human hematopoietic niche formation. Blood, 125(2), 249-260.
DOI Scopus94 Europe PMC74
2015 Sinha, S., Thomas, D., Yu, L., Gentles, A., Jung, N., Corces-Zimmerman, M., . . . Majeti, R. (2015). Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. Blood, 125(2), 316-326.
DOI Scopus21 Europe PMC14
2015 Reinisch, A., Chan, S., Thomas, D., & Majeti, R. (2015). Biology and clinical relevance of acute myeloid leukemia stem cells. Seminars in Hematology, 52(3), 150-164.
DOI Scopus26 Europe PMC23
2015 Chan, S., Thomas, D., Corces-Zimmerman, M., Xavy, S., Rastogi, S., Hong, W., . . . Majeti, R. (2015). Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nature Medicine, 21(2), 178-184.
DOI Scopus183 Europe PMC142
2014 Busfield, S., Biondo, M., Wong, M., Ramshaw, H., Lee, E., Ghosh, S., . . . Nash, A. (2014). Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia, 28(11), 2213-2221.
DOI Scopus65 WoS62 Europe PMC49
2013 Huang, M., Thomas, D., Li, M., Feng, W., Chan, S., Majeti, R., & Mitchell, B. (2013). Role of cysteine 288 in nucleophosmin cytoplasmic mutations: Sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia, 27(10), 1970-1980.
DOI Scopus18 Europe PMC15
2013 Lonic, A., Powell, J., Kong, Y., Thomas, D., Holien, J., Truong, N., . . . Guthridge, M. (2013). Phosphorylation of serine 779 in fibroblast growth factor receptor 1 and 2 by protein Kinase C(epsilon) regulates Ras/mitogen-activated protein kinase signaling and neuronal differentiation. Journal of Biological Chemistry, 288(21), 14874-14885.
DOI Scopus9 WoS10 Europe PMC8
2013 Thomas, D., Powell, J., Vergez, F., Segal, D., Nguyen, N., Baker, A., . . . Guthridge, M. (2013). Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 122(5), 738-748.
DOI Scopus34 WoS32 Europe PMC25
2013 Lim, Y., Wright, J., Attema, J., Gregory, P., Bert, A., Smith, E., . . . Goodall, G. (2013). Epigenetic modulation of the miR-200 family is associated with transition to a breast cancer stem-cell-like state. Journal of Cell Science, 126(10), 2256-2266.
DOI Scopus110 WoS100 Europe PMC84
2013 Thomas, D., Powell, J., Green, B., Barry, E., Ma, Y., Woodcock, J., . . . Guthridge, M. (2013). Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. PLoS Biology, 11(3), 1-14.
DOI Scopus17 WoS14 Europe PMC14
2012 Hercus, T., Broughton, S., Ekert, P., Ramshaw, H., Perugini, M., Grimbaldeston, M., . . . Lopez, A. (2012). The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors, 30(2), 63-75.
DOI Scopus36 WoS32 Europe PMC27
2010 Lopez, A., Hercus, T., Ekert, P., Littler, D., Guthridge, M., Thomas, D., . . . Parker, M. (2010). Molecular basis of cytokine receptor activation. IUBMB Life, 62(7), 509-518.
DOI Scopus49 WoS46 Europe PMC34
2010 Roberts, K., Smith, A., McDougall, F., Carpenter, H., Horan, M., Neviani, P., . . . Verrills, N. (2010). Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT<sup>+</sup> cancers. Cancer Research, 70(13), 5438-5447.
DOI Scopus96 WoS94 Europe PMC62
2009 Jin, L., Lee, E., Ramshaw, H., Busfield, S., Peoppl, A., Wilkinson, L., . . . Lock, R. (2009). Monoclonal antibody-mediated targeting of CD123, IL-3 receptor α chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 5(1), 31-42.
DOI Scopus322 WoS295 Europe PMC245
2009 Powell, J., Thomas, D., Barry, E., Kok, C., McClure, B., Tsykin, A., . . . Guthridge, M. (2009). Expression profiling of a hemopoietic cell survival transcriptome implicates osteopontin as a functional prognostic factor in AML. Blood, 114(23), 4859-4870.
DOI Scopus41 WoS39 Europe PMC34
2009 Hercus, T., Thomas, D., Guthridge, M., Ekert, P., King-Scott, J., Parker, M., & Lopez, A. (2009). The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease. Blood, 114(7), 1289-1298.
DOI Scopus170 WoS169 Europe PMC127
2008 Lee, S., Ho, S., Thomas, D., Giri, P., Lee, H., Sia, H., . . . Sullivan, T. (2008). A partial nucleated differential cell count of the bone marrow aspirate that is independent of peripheral blood dilution. International Journal of Laboratory Hematology (Print Edition), 30(6), 473-479.
DOI Scopus2 WoS1 Europe PMC1
2006 Mitchell, E., Thomas, D., & Burnet, R. (2006). Testosterone improves motor function in Parkinson's disease. Journal of Clinical Neuroscience, 13(1), 133-136.
DOI Europe PMC15
2006 Guthridge, M., Powell, J., Barry, E., Stomski, F., Mc Clure, B., Ramshaw, H., . . . Lopez, A. (2006). Growth factor pleiotropy is controlled by a receptor Tyr/Ser motif that acts as a binary switch. EMBO Journal, 25(3), 479-489.
DOI Scopus50 WoS49 Europe PMC42
2004 Thomas, D., Vadas, M., & Lopez, A. (2004). Regulation of haematopoiesis by growth factors - emerging insights and therapies. Expert Opinion on Biological Therapy, 4(6), 869-879.
DOI Scopus14 WoS13 Europe PMC12
1999 Stomski, F., Dottore, M., Winnall, W., Guthridge, M., Woodcock, J., Bagley, C., . . . Lopez, A. (1999). Identification of a 14-3-3 binding sequence in the common B chain of the granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-3 (IL-3), and IL-5 receptors that is serine-phosphorylated by GM-CSF. Blood, 94(6), 1933-1942.
Scopus43 WoS42 Europe PMC23
1998 Guthridge, M., Stomski, F., Thomas, D., Woodcock, J., Bagley, C., Berndt, M., & Lopez, A. (1998). Mechanism of activation of the GM-CSF, IL-3, and IL-5 family of receptors. Stem Cells, 16(5), 301-313.
DOI Scopus125 WoS121 Europe PMC80
Year Citation 2005 Thomas, D., Guthridge, M., Woodcock, J., & Lopez, A. (2005). Protein Signaling in Development and Growth Factor Responses (Vol. 67). G. Schatten (Ed.), ELSEVIER ACADEMIC PRESS INC.
DOI Scopus23 WoS24 Europe PMC12
|Jan 2017-Jan 2022||Discovery of Synthetic Lethal Targets for Recurrent Epigenetic Mutations in Acute Myeloid Leukemia/APP ID 88686 (Thomas)||Thomas, D.||National Cancer Institute||USD$1,040,000|
|Jul 2018-Jul 2019||
Potent and Selective ACC1 inhibitor for Cancer with IDH1 Mutations
|Majeti, R.||Stanford University||USD$75,000|
|Jul 2014-Jan 2015||Data-Mining for Synthetic Lethal Targets in Acute Myeloid Leukemia||
Majeti, R. Dill, D.L.
|National Institutes of Health||USD$|
Jan 2014-Jan 2015
|SA PATH Equipment Grant/GNT9000253||Lopez, A. Hughes, T. Revesz, T.||National Health and Medical Research Council||AUD$9,634|
|Jan 2012-Dec 2017||Targetting Quiescence Signalling Pathways in AML Stem Cells/APP1037514||Thomas, D.||National Health and Medical Research Council|
Connect With Me